Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Reardon Andrew sold 5,000 Ligand Pharmaceuticals Incorporated shares (Form 4)
Traded Jun 1, 2026 · Filed Jun 2, 2026
On Jun 1, 2026, Reardon Andrew (CLO & Secretary) sold 5,000 Ligand Pharmaceuticals Incorporated shares at an average US$227.06 for US$1.14M under a trading plan, leaving 41,382 shares. Filed Jun 2, 2026 (Form 4).
- Sold
- 5,000 shares
- Price
- US$227.06 average (US$223.95 to US$230.41)
- Value
- US$1.14M
- Holding after
- 41,382 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- CLO & Secretary
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | Option exercise | 5,000 | US$52.27 | 46,382 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 491 | US$223.95 | 45,891 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 677 | US$225.20 | 45,214 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 1,432 | US$225.97 | 43,782 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 400 | US$226.78 | 43,382 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 584 | US$228.57 | 42,798 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 1,216 | US$229.47 | 41,582 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 200 | US$230.41 | 41,382 | Direct |
Source
Related
- Ligand Pharmaceuticals Incorporated
- Reardon Andrew
- Ligand Pharmaceuticals Incorporated shareholders
- Form 4 · Reardon Andrew · Oct 6, 2026
- Form 4 · Reardon Andrew · Sep 8, 2026
- Form 4 · Reardon Andrew · Aug 4, 2026
- Form 4 · Reardon Andrew · Jul 6, 2026
- Form 4 · Reardon Andrew · May 4, 2026
- Form 4 · Zimmermann Martine · Sep 24, 2026
- Form 4 · Zimmermann Martine · Sep 14, 2026
- Form 4 · Espinoza Octavio · Aug 14, 2026
- Form 4 · Haas Jason · Aug 14, 2026
- Schedule 13G · Invesco Ltd. · Aug 13, 2026